Abstract: Compounds of Formula (I), wherein represents a single bond when G is —OH and double bond when G is —O; R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; R3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy; X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom; Het is heterocyclyl or heteroaryl; n is an integer from 1 to 6; are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and 4 i gastrointestinal systems mediated through muscarinic receptors.

Abstract: The present invention relates to isoxazoline derivatives of structure Ia, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CNS disorders, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type IV inhibitors.

Abstract: A voltage-level translator includes an input node, a differential amplifier, first and second output transistors, and a constant current source. The input node receives an input signal. The differential amplifier produces a voltage swing at an amplifier node based at least in part on a difference between the input signal and a voltage supply. The first output transistor provides a substantially constant current to the output node. The voltage swing produced by the differential amplifier prevents forward biasing of the second output transistor. The constant current source provides a substantially constant current both to the differential amplifier and through the first output transistor. The translator outputs a first voltage in an output voltage range at the output node when the input signal is at a high voltage, and outputs a second voltage in the output voltage range at the output node when the input signal is at a low voltage.

Abstract: This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

Abstract: A peak current modeling method and system for modeling peak current demand of an integrated circuit (IC) block such as, e.g., a compilable memory instance. A current demand curve associated with the IC for a particular IC block event is obtained via simulation, for example. A defined time region associated with the particular IC block event is divided into multiple time segments, whereupon at least a first current value and a second current value for each time segment is obtained based on the current demand curve. Thereafter, the current demand curve is approximated, on a segment-by-segment basis, using a select approximate waveform depending on a relationship between the first and second current values.

Abstract: An output buffer circuit includes a first output transistor having a source terminal connected to a voltage supply and a drain terminal connected to an output node. The first output transistor is capable of coupling the output node to the voltage supply when the input signal is at a high voltage in the input voltage range. The circuit also includes a second output transistor having a drain terminal connected to the output node and a source terminal connected to ground. The second output transistor is capable of coupling the output node to ground when the input signal is at a low voltage in the input voltage range. The circuit further includes a current-limiting circuit coupled to a gate terminal of the first output transistor and capable of limiting a current flowing through the gate terminal when the first output transistor is turned on. The output node outputs an output signal in an output voltage range, wherein a high voltage of the output voltage range exceeds the high voltage of the input voltage range.

Abstract: The present invention generally relates to muscarinic receptor antagonists of formula I, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Formula (I) wherein Het: is heterocyclyl or heteroaryl X: O, S or NR1 and the other substituents are defined as in the claims.

Abstract: The present invention relates to standardized extracts of Boerhaavia diffusa, wherein the extracts have anti inflammatory and analgesic activities. The present invention also includes bioassay guided fractionation of Boerhaavia diffusa leading to the identification of bioactive markers; processes for the isolation of the bioactive markers; processes for the preparation of the extracts enriched with bioactive markers from Boerhaavia diffusa; pharmaceutical compositions comprising bioactive markers, or standardized extracts of Boerhaavia diffusa and methods of standardization of the extracts.

Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders.

Abstract: Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer.

Abstract: A level-shifting circuit includes an input node, a first output transistor, a second output transistor, a pull-up transistor, and an output node. The input node receives an input signal. The first output transistor turns on when the input signal is at a first voltage level and couples an output node to a positive supply voltage when turned on. The second output transistor, a bipolar junction transistor (BJT), couples the output node to a negative supply voltage when turned on. The pull-up transistor turns on when the input signal is at a second voltage level and generates a voltage at a base terminal of the second output transistor that turns the second output transistor on. Additionally, the level-shifting circuit generates, at the output node, an output signal with a voltage swing that includes a positive voltage range and a negative voltage range.

Abstract: The present invention relates to 5-lipoxygenase inhibitors. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory, and autoimmune diseases. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.

Abstract: The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The present invention also relates to processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated through muscarinic receptors. Formula (I) or a pharmaceutically accepted salt, pharmaceutically acceptable solvate, enantiomers, diastereomer, polymorph or N-oxide thereof, wherein X is.

Abstract: The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV.

Abstract: Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredient such as muscarinic receptor antagonists (MRA), ?2-agonists, p38 MAP Kinase inhibitors, or corticosteroids and optionally one or more pharmaceutically acceptable excipients. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.

Abstract: Formula 1 is an antioxidant compound, wherein R, R1, or D is an antioxidant substituent; R and D are each independently selected from hydrogen or groups containing cysteine, thiols, disulfides, amino acids, amines, amides, or carboxylic acids; when one of R or D is hydrogen, the other includes a thiol, disulfide, or carboxylic acid; A is CO, SO, SO2, or C?S; E is one or more ring groups which are aromatic, carbocyclic, and/or heterocyclic 5, 6 and 7 membered rings being mono, bi, tri, tetra, penta, hexa, hepta or octa cyclic fused rings that are substituted or unsubstituted, each heterocyclic ring can include hetero atoms chosen from to O, S, N, Se, or P; each R1 is at a para, meta, and/or ortho position; n is 1, 2, 3, 4, or 5 for each ring; and each R1 is hydrogen or an antioxidant substituent.

Abstract: The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV Formula (XIV).

Abstract: A switching circuit can have a plurality of first signal lines of a programmable logic device, a plurality of second signal lines of the programmable logic device, and a plurality of switch elements. Each switch element can selectively couple one first signal line to a second signal line and include one or more switch junction field effect transistors (JFETs) having a first control gate separated from a second control gate by a channel region.

Abstract: The present invention relates to oxazine derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CMS disorders, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type IV inhibitors.

Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis or allergic rhinitis. Pharmacological compositions containing the compounds of the present invention and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.